Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3962 |
Name | follicular thyroid carcinoma |
Definition | A differentiated thyroid gland carcinoma that has_material_basis_in follicular cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma thyroid gland adenocarcinoma differentiated high-grade thyroid carcinoma follicular thyroid carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PTEN R130* | MK2206 | follicular thyroid carcinoma | sensitive | detail... |
RET fusion | Selpercatinib | follicular thyroid carcinoma | sensitive | detail... |
RET fusion | Pralsetinib | follicular thyroid carcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib | follicular thyroid carcinoma | sensitive | detail... |
BRAF V600E | Vemurafenib | follicular thyroid carcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | follicular thyroid carcinoma | sensitive | detail... |
MLH1 negative | Pembrolizumab | follicular thyroid carcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | follicular thyroid carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01723202 | Phase II | Dabrafenib + Trametinib Dabrafenib | Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer | Unknown status | USA | 0 |
NCT02145143 | Phase 0 | Vemurafenib | Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study | Active, not recruiting | USA | 0 |
NCT02152995 | Phase II | Trametinib | Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT02211222 | Phase I | Lenvatinib | An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer | Approved for marketing | USA | 0 |
NCT02393690 | Phase II | Selumetinib | Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer | Completed | USA | 0 |
NCT02456701 | Phase I | CDX-3379 + Vemurafenib | Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | Completed | USA | 0 |
NCT02702388 | Phase II | Lenvatinib | Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile | Completed | USA | SWE | ROU | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 2 |
NCT02973997 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03215095 | Phase I | Durvalumab | RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers | Active, not recruiting | USA | 0 |
NCT03244956 | Phase II | Trametinib Dabrafenib + Trametinib | Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE) | Unknown status | FRA | 0 |
NCT03732495 | Phase II | Denosumab + Lenvatinib | Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS) | Unknown status | FRA | 0 |
NCT03753919 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) | Terminated | ESP | 0 |
NCT03914300 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT04321954 | Phase II | Lenvatinib | Lenvatinib in Locally Advanced Invasive Thyroid Cancer | Recruiting | USA | 0 |
NCT04462471 | Phase I | Copanlisib + Vemurafenib | Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers | Completed | USA | 0 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05660954 | Phase II | Cabozantinib | Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. (CABOTHYROID) | Active, not recruiting | ESP | 0 |
NCT06007924 | Phase II | Defactinib + RO5126766 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Recruiting | USA | 0 |
NCT06440850 | Phase II | Cobimetinib + Vemurafenib | Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | Recruiting | USA | 0 |